Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Coherus Oncology Inc (CHRS)

Coherus Oncology Inc (CHRS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 243,638
  • Shares Outstanding, K 149,471
  • Annual Sales, $ 266,960 K
  • Annual Income, $ 28,510 K
  • EBIT $ -178 M
  • EBITDA $ -172 M
  • 60-Month Beta 0.99
  • Price/Sales 0.68
  • Price/Cash Flow 5.87
  • Price/Book 2.26

Options Overview Details

View History
  • Implied Volatility 167.57% (+18.36%)
  • Historical Volatility 129.45%
  • IV Percentile 39%
  • IV Rank 13.41%
  • IV High 670.52% on 11/17/25
  • IV Low 89.67% on 08/13/25
  • Expected Move (DTE 27) 0.4080 (25.03%)
  • Put/Call Vol Ratio 0.07
  • Today's Volume 212
  • Volume Avg (30-Day) 1,586
  • Put/Call OI Ratio 0.18
  • Today's Open Interest 29,504
  • Open Int (30-Day) 24,178
  • Expected Range 1.2220 to 2.0380

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.38
  • Number of Estimates 3
  • High Estimate -0.36
  • Low Estimate -0.41
  • Prior Year -0.44
  • Growth Rate Est. (year over year) +13.64%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.5500 +5.16%
on 01/21/26
2.6158 -37.69%
on 01/27/26
+0.0800 (+5.16%)
since 01/20/26
3-Month
1.0900 +49.54%
on 11/21/25
2.6158 -37.69%
on 01/27/26
+0.5300 (+48.18%)
since 11/20/25
52-Week
0.7100 +129.58%
on 06/23/25
2.6158 -37.69%
on 01/27/26
+0.5300 (+48.18%)
since 02/20/25

Most Recent Stories

More News
Coherus Oncology, Inc. Announces Closing of Public Offering of Common Stock

–The Offering was led by healthcare-dedicated investors including Janus Henderson Investors, HBM Healthcare Investments and Samsara BioCapital– REDWOOD CITY, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE)...

CHRS : 1.6300 (-4.68%)
Coherus Oncology, Inc. Announces Pricing of Public Offering of Common Stock

REDWOOD CITY, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (“Coherus” or the “Company”) (NASDAQ: CHRS), today announced the pricing of an underwritten public offering of...

CHRS : 1.6300 (-4.68%)
Coherus Oncology, Inc. Announces Proposed Public Offering of Common Stock

REDWOOD CITY, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (“Coherus” or the “Company”) (NASDAQ: CHRS), today announced a proposed underwritten public offering of its common...

CHRS : 1.6300 (-4.68%)
Targeted Precision: Rare Disease Assets Attract Record Regulatory Momentum

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – Baystreet.ca News Commentary – Genomics-driven cancer diagnostics are accelerating market growth, with the genomics in cancer care market...

ONCY : 0.9640 (-3.60%)
IDYA : 31.98 (-2.80%)
ZLAB : 20.04 (-0.20%)
CHRS : 1.6300 (-4.68%)
HALO : 70.98 (-1.47%)
Coherus Management to Present at the 44th Annual J.P. Morgan Healthcare Conference

REDWOOD CITY, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS) today announced that senior management will present at the 44th Annual J.P. Morgan Healthcare Conference...

CHRS : 1.6300 (-4.68%)
Coherus Oncology Announces Publication in Molecular Cancer Therapeutics Highlighting the Strong Pharmacology of Investigational CCR8 Antibody Tagmokitug (CHS-114)

-Coherus Oncology formally introduces non-proprietary name:  tagmokitug- -Publication shows picomolar affinity for CCR8 with no off-target binding and proof-of- mechanism in preclinical and clinical...

CHRS : 1.6300 (-4.68%)
Coherus Announces Six-Year JUPITER-02 Follow-up Results Showing LOQTORZI® plus Chemotherapy Nearly Doubles Median Overall Survival in Nasopharyngeal Carcinoma

REDWOOD CITY, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS) today announced compelling six-year overall survival (OS) follow-up results from the Phase 3 JUPITER-02 trial...

CHRS : 1.6300 (-4.68%)
Coherus Oncology Presents at SITC Clinical Multiomic Biomarker Data for CHS-114, a Highly Selective anti-CCR8 Cytolytic Antibody

– CHS-114 demonstrated robust and selective depletion of CCR8+ Tregs as well as favorable immune remodeling in tumor tissue from head and neck squamous cell carcinoma (HNSCC) patients – – CHS-114...

CHRS : 1.6300 (-4.68%)
Coherus Oncology: Q3 Earnings Snapshot

Coherus Oncology: Q3 Earnings Snapshot

CHRS : 1.6300 (-4.68%)
Coherus Oncology Reports Third Quarter 2025 Financial Results and Provides Business Update

– CHS-114, a highly selective Treg depleter, clinical program expanded to include colorectal cancer – – Q3 2025 ending cash, cash equivalents and marketable securities of $191.7 million –...

CHRS : 1.6300 (-4.68%)

Business Summary

Coherus is a fully integrated commercial-stage innovative oncology company. Coherus, formerly known as Coherus BioSciences Inc., is based in REDWOOD CITY, Calif.

See More

Key Turning Points

3rd Resistance Point 1.8265
2nd Resistance Point 1.7833
1st Resistance Point 1.7066
Last Price 1.6300
1st Support Level 1.5867
2nd Support Level 1.5435
3rd Support Level 1.4668

See More

52-Week High 2.6158
Fibonacci 61.8% 1.8878
Fibonacci 50% 1.6629
Last Price 1.6300
Fibonacci 38.2% 1.4380
52-Week Low 0.7100

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar